Company intelligence / Profile preview

NiKang Therapeutics

Wilmington, Delaware, United Statesnikangtx.com ↗

Ownership: Private
Employees: ~42
Development stage: Phase 2

Overview

NiKang has three programs in clinical trials: NKT2152 (HIF2α inhibitor) in Phase 1b/2 for hepatocellular carcinoma and clear cell renal cell carcinoma, NKT3447 (CDK2 inhibitor), and NKT3964 (CDK2 degrader) which completed first cohort dosing in Phase 1 in March 2025.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

nkt3447

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on NiKang Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NiKang Therapeutics.

Explore the full profile